These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16524070)

  • 21. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
    Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
    J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation as treatment for myelofibrosis.
    Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
    Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic stem-cell transplantation using umbilical-cord blood cells.
    Rocha V; Garnier F; Ionescu I; Gluckman E;
    Rev Invest Clin; 2005; 57(2):314-23. PubMed ID: 16524073
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences between the different conditioning regimens for allogeneic stem cell transplantation.
    Schattenberg AV; Levenga TH
    Curr Opin Oncol; 2006 Nov; 18(6):667-70. PubMed ID: 16988592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoietic stem cell transplantation in the elderly.
    Shapira MY; Tsirigotis P; Resnick IB; Or R; Abdul-Hai A; Slavin S
    Crit Rev Oncol Hematol; 2007 Oct; 64(1):49-63. PubMed ID: 17303434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?
    Anderlini P; Champlin RE
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):599-602. PubMed ID: 16737932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
    Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; Craddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH
    Bone Marrow Transplant; 2008 Dec; 42(12):783-9. PubMed ID: 18724393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases.
    Satwani P; Morris E; Bradley MB; Bhatia M; van de Ven C; Cairo MS
    Pediatr Blood Cancer; 2008 Jan; 50(1):1-8. PubMed ID: 17668859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
    Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent progress in pediatric stem cell transplantation].
    Matsumoto K; Kato K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):187-93. PubMed ID: 17301525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.